Relation between bone mineral density and oxidative stress in Egyptian patients with chronic kidney disease: a cross sectional study

Table 4 Laboratory findings among the studied groups

Marker	Control N = 150	Total studied patients (N = 150)	P1	Stage I-II N = 45	Stage III-IV N = 50	Stage V N = 55	P2
Creat(mg/dl) (M: 0.7–1.3, F: 0.6–1.1) mg/dl	0.86 ± 0.17	4.25 ± 1.21	0.01	1.69 ± 0.42	2.49 ± 0.44	5.36 ± 1.37	0.001
Ca (mg/dl) (8.5–10.2) mg/dl	9.76 ± 0.62	8.37 ± 1.18	0.01	9.73 ± 0.54	9.00 ± 0.71	8.25 ± 1.29	0.001
Phos (mg/dl) (2.5–4.5) mg/dl	3.32 ± 0.47	4.21 ± 0.84	0.01	3.95 ± 0.73	4.28 ± 0.93	4.60 ± 1.09	0.01
PTH (pg/ml) (15–65) pg/ml	51.40 ± 6.16	180.39 ± 13.55	0.001	48.90 ± 7.75	165.50 ± 3.55	341.64 ± 21.66	0.001
Alb (g/dl) (3.4–5.4) g/dl	3.79 ± 0.16	3.33 ± 0.41	0.001	3.57 ± 0.34	3.35 ± 0.65	3.28 ± 0.45	0.05
Vit D(ng/ml) (20–40) ng/ml	28.30 ± 6.97	13.77 ± 6.32	0.001	19.80 ± 4.71	13.10 ± 5.02	8.91 ± 3.80	0.001
ALP (IU/L) (44–147) IU/L	55.40 ± 1.70	139.90 ± 9.18	0.001	62.80 ± 13.16	128.90 ± 8.08	143.82 ± 10.23	0.001
8-OHdG (pg/ml)	1.86 ± 7.60	5.78 ± 16.10	0.001	2.58 ± 09.19	3.78 ± 06.0	6.63 ± 07.01	0.001
MDA (nmol/l)	2.37 ± 0.41	6.42± 1.27	0.001	4.58 ± 2.18	6.61 ± 1.31	7.91 ± 1.94	0.001
PON-1 (U/L)	116.8 ± 9.22	50.59 ± 15.80	0.001	95.78 ± 7.13	51.45 ± 0.14	36.91 ± 16.50	0.001

Creat: Creatinine, Cal: Calcium, Phos: Phosphorus, Alb: Albumin, Vit D: Vitamin D, ALP: Alkaline Phosphatase, 8OHdG: 8-Hydroxy-2’-deoxyguanosine, MDA: Malondialdehyde, PON-1: Paraoxonase-1, PTH: parathyroid hormone. P1 = significance by Student’s t test between total cases and control, P2 = ANOVA between subgroups. p < 0.05 by post hoc analysis, Stage 1–2 vs. Stage 3–4 and Stage 5

ISSN: 1471-2369